For the quarter ended March 2025, BioMarin Pharmaceutical (BMRN) reported revenue of $745.15 million, up 14.8% over the same period last year. EPS came in at $1.13, compared to $0.71 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $736.99 million, representing a surprise of +1.11%. The company delivered an EPS surprise of +20.21%, with the consensus EPS estimate being $0.94.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenues: $734.64 million compared to the $728.44 million average estimate based on nine analysts. The reported number represents a change of +15.2% year over year.
- Revenues- Royalty and other revenues: $10.50 million versus the nine-analyst average estimate of $9.70 million. The reported number represents a year-over-year change of -4.7%.
- Revenues- Net Product Revenues- NAGLAZYME: $114 million compared to the $110.87 million average estimate based on eight analysts. The reported number represents a change of +8% year over year.
- Revenues- Net Product Revenues- VIMIZIM: $188 million versus the eight-analyst average estimate of $192.35 million. The reported number represents a year-over-year change of -2.4%.
- Revenues- Net Product Revenues- PALYNZIQ: $93 million versus the eight-analyst average estimate of $96.89 million. The reported number represents a year-over-year change of +22.9%.
- Revenues- Net Product Revenues- VOXZOGO: $214 million compared to the $214.98 million average estimate based on eight analysts. The reported number represents a change of +40% year over year.
- Revenues- Net Product Revenues- ROCTAVIAN: $11 million versus $10.70 million estimated by eight analysts on average.
- Revenues- Net Product Revenues- KUVAN: $25 million compared to the $23.53 million average estimate based on eight analysts. The reported number represents a change of -30.4% year over year.
- Revenues- Net Product Revenues- ALDURAZYME: $49 million versus the eight-analyst average estimate of $38.75 million. The reported number represents a year-over-year change of +38.8%.
- Revenues- Net Product Revenues- BRINEURA: $40 million versus the eight-analyst average estimate of $43.88 million. The reported number represents a year-over-year change of +2.6%.
View all Key Company Metrics for BioMarin here>>>
Shares of BioMarin have returned -6.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
